BridgeMD
New treatment option for Acute Kidney Disease
Official title AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease
ClinicalTrials.gov ID: NCT07182422
What this study is testing
What is AST-120 (Kremezin®)?
AST-120 (Kremezin®) is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for acute kidney disease.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The primary goal of this clinical trial is to evaluate the efficacy of AST-120 (Kremezin®) in combination with standard care in reducing the levels of protein-bound uremic toxins (PBUTs), specifically indoxyl sulfate (IS) and p-cresyl sulfate (p-CS), in patients with acute kidney disease (AKD). The trial aims to assess whether AST-120 can prevent further renal deterioration and slow the progression from AKD to chronic kidney disease (CKD) by mitigating the accumulation of PBUTs.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Inclusion/
You likely can't join if
- ： Inclusion criteria
- Age between 18 and 80 years.
- Diagnosis of acute kidney disease (AKD) during hospitalization, with AKD stage 2 or 3 according to the KDIGO-AKD criteria, defined by an increase in...
- Post-discharge estimated glomerular filtration rate (eGFR) between 30 and 60 ml/min/1.73m², calculated using the MDRD equation.
- Hospitalization duration not exceeding 1 month. Exclusion criteria
- Patients with cancer or hematological malignancies.
See the full eligibility criteria
- Inclusion/
- ： Inclusion criteria
- Age between 18 and 80 years.
- Diagnosis of acute kidney disease (AKD) during hospitalization, with AKD stage 2 or 3 according to the KDIGO-AKD criteria, defined by an increase in serum creatinine to 2 times or more from baseline within 7 to 90 days.
- Post-discharge estimated glomerular filtration rate (eGFR) between 30 and 60 ml/min/1.73m², calculated using the MDRD equation.
- Hospitalization duration not exceeding 1 month. Exclusion criteria
- Patients with cancer or hematological malignancies.
- Patients with AKD etiologies that cannot be managed in an outpatient setting (e.g., diabetic foot, obstructive uropathy with sepsis, cirrhosis). 1\. Patients presenting any of the following conditions, considered as...
- Bedridden.
- Requiring nasogastric tube feeding.
- Long-term use of oxygen therapy.
- Use of urinary catheters. Patients unsuitable for AST-120 treatment, including:
- Patients with severe constipation (defined as requiring the daily use of more than one laxative).
- Patients with abnormal liver function (defined as ALT levels greater than 5 times the upper limit or total bilirubin \> 2mg/dL).
- Patients with a history of peptic ulcers within the last month.
- Pregnant women.
- Patients allergic to the study drug.
The study team makes the final eligibility decision.
Where it's taking place
- Taoyuan, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Taoyuan, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.